Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07372989 · ClinicalTrials.gov registry record · Phase 1
Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease
A Phase 1 study of Lung Diseases, Interstitial, sponsored by Maule Stem Cell Research Institute.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT07372989: Recruiting Phase 1 study of Lung Diseases, Interstitial, sponsored by Maule Stem Cell Research Institute.
NCT07372989 is a Phase 1 study of Lung Diseases, Interstitial that is actively recruiting participants, run by Maule Stem Cell Research Institute. The registered enrollment target is 50 participants, below the 12,504-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07372989, a Phase 1 study of Lung Diseases, Interstitial, is actively recruiting participants, sponsored by Maule Stem Cell Research Institute.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic inflammation, and dysregulated fibroblast activation, ultimately leading to impaired gas exchange and respiratory failure. Current treatments, such as antifibrotic agents (pirfenidone and nintedanib), slow disease progression but do not reverse existing fibrosis or restore lung function. This pilot study will generate critical safety and preliminary efficacy data to inform future larger-scale trials and optimize dosing strategies for nebulized HAF-based therapeutics in ILD.
Primary Outcome
Outcome Measure Description: Incidence of treatment-emergent serious adverse events (TE-SAEs) in participants receiving nebulized Matrix (HAF) therapy. Unit of Measure: Number of participants with ≥1 TESAE
Conditions Studied
Interventions
- BIOLOGICAL Matrix
Study Locations (1)
Florida
- Maule Stem Cell Research Institute - Venice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2026-02 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 1 |
What NCT07372989 shows while recruiting
NCT07372989 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 12,504-participant average among 10 other Lung Diseases, Interstitial trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Lung Diseases, Interstitial appearing as the primary indexed condition, and to 1 intervention - of which Matrix is the first listed.
NCT07372989 reports a single indexed study location in Florida.
Frequently Asked Questions
What is clinical trial NCT07372989 about?
NCT07372989 is a clinical study titled "Nebulized Human Amniotic Fluid in Patients With Interstitial Lung Disease". This is a Phase I, pilot clinical trial designed to evaluate the safety and exploratory efficacy of nebulized diluted amniotic fluid, Matrix (HAF-Matrix) in adults with interstitial lung disease (ILD). ILDs are progressive fibrotic disorders characterized by aberrant wound-healing responses, chronic...
What is the current status of trial NCT07372989?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2026-02. Estimated completion is 2028-10-01.
What conditions does trial NCT07372989 study?
This clinical trial studies the following conditions: Lung Diseases, Interstitial.
What interventions are being tested in trial NCT07372989?
The interventions under investigation include: Matrix (BIOLOGICAL).
Who is sponsoring clinical trial NCT07372989?
This trial is sponsored by Maule Stem Cell Research Institute, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07372989 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lung Diseases, Interstitial
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07372989's enrollment target sits among peer trials
50 7th of 10 higher than 4 of 10 other Lung Diseases, Interstitial trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Lung Diseases, Interstitial trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease
RECRUITING · Phase 3
-
Dorothy P. and Richard P. Simmons Center for ILD Research Registry
RECRUITING
-
H01 in Adults With Interstitial Lung Disease (The SOLIS Study)
RECRUITING · Phase 2
-
Physical Activity and Quality of Life in Fibrotic Lung Diseases After Initiating Anti-fibrotic Therapy and Pulmonary Rehabilitation
RECRUITING · NA
-
Cough Capture as a Portal Into the Lung
RECRUITING
-
Early Feasibility Study Evaluating the 3P-100 Device in Subjects With PH-ILD
ACTIVE NOT RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia